A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC
1996

Docetaxel for Advanced Breast Cancer

Sample size: 39 publication Evidence: moderate

Author Information

Author(s): V Dieras, B Chevallier, P Kerbrat, I Krakowski, H Roche, JL Misset, MA Lentz, N Azli, M Murawsky, A Riva, P Pouillart, P Fumoleau

Primary Institution: Institut Curie, Paris

Hypothesis

Is docetaxel effective as first-line chemotherapy for patients with advanced breast cancer?

Conclusion

Docetaxel at a dose of 75 mg/m² is confirmed to be an active agent in treating advanced breast cancer.

Supporting Evidence

  • An overall response rate of 52% was achieved in evaluable patients.
  • Grade 4 neutropenia occurred in 82% of patients.
  • The median duration of response was 34 weeks.

Takeaway

This study tested a medicine called docetaxel to see if it helps women with advanced breast cancer. It worked for about half of the women who tried it.

Methodology

A phase II, multicentre, open-label, non-randomised study where patients received docetaxel intravenously every 3 weeks.

Potential Biases

Potential selection bias due to non-randomized design.

Limitations

The study had a small sample size and was not randomized.

Participant Demographics

39 women, median age 51 years, with advanced breast cancer.

Statistical Information

Confidence Interval

95% CI 33-70%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication